Baidu
map

中国上市的适应症!罗氏VENTANA PD-L1(SP263)检测作为治疗尿路上皮癌的伴随诊断获批上市

2020-05-15 MedSci MedSci

2020年5月15日,全球体外诊断领导者罗氏诊断宣布VENTANA PD-L1(SP263)检测正式在中国获批上市。

2020年5月15日,全球体外诊断领导者罗氏诊断宣布VENTANA PD-L1(SP263)检测正式在中国获批上市。该检测通过对肿瘤微环境中的肿瘤及免疫细胞进行染色及评分,以评估患者的PD-L1表达水平,为临床医生提供指导治疗决策的信息,改善尿路上皮癌患者的生活与生存质量。

 
 
尿路上皮癌是膀胱癌的主要组织学类型,约占所有膀胱癌的90%。据《2018年全球癌症统计》显示,2018年全球膀胱癌新发病例549,393例,死亡199,922例。其中,我国膀胱癌预计新发病例82,270例,预计死亡病例38,208例。

作为当前肿瘤治疗领域中最具前景的研究方向之一,肿瘤免疫治疗是通过调动机体的免疫系统,增强抗肿瘤免疫力,从而抑制和杀伤肿瘤细胞。免疫治疗临床研究进展中,程序性死亡因子1(programmed death 1,PD-1)/程序性死亡因子配体1(programmed death ligand 1, PD-L1)免疫检查点抑制剂近年来在肿瘤治疗中取得突破性进展,为肿瘤诊疗领域开启了全新模式。PD-L1是一种免疫抑制蛋白,可影响人体抵抗癌症的能力。研究证实,PD-L1高表达患者更可能从免疫治疗中获益。因此,了解PD-L1表达水平对指导临床诊疗具有重要价值。
 

作为一种辅助诊断工具,VENTANA PD-L1(SP263)检测用于检测PD-L1在尿路上皮癌的肿瘤细胞和免疫细胞的表达,为临床医生评估患者的PD-L1状态。据悉,该检测适用于罗氏诊断BenchMark ULTRA全自动免疫组化染色平台。

罗氏诊断中国总经理姚国樑先生表示:“目前,尿路上皮癌诊疗领域仍存在着远未被满足的临床需求,医生和患者都亟需一种更为有效的治疗方式。精准治疗,检测先行。此次罗氏VENTANA PD-L1(SP263)检测上市并与百济神州的尿路上皮癌免疫治疗产品达成合作,体现了罗氏诊断中国通过创新型诊断解决方案持续致力于个体化医疗的承诺。尿路上皮癌是VENTANA PD-L1(SP263)检测在中国上市的首个适应症,未来,我们将继续推动该项检测的更多适应症在中国获批,以造福更多中国患者。”
 
关于VENTANA PD-L1(SP263)检测

VENTANA PD-L1(SP263)检测,用于越来越多的癌症适应症中的程序性死亡配体(PD-L1)的定性检测。该检测适用于BenchMark ULTRA全自动免疫组化染色平台。VENTANA PD-L1(SP263)用于评估PD-L1在尿路上皮癌的肿瘤或免疫细胞膜中的表达,是帮助确定尿路上皮癌免疫治疗应答可能性的一种有效的工具。
 
关于罗氏

罗氏是全球制药与诊断的先驱,致力于推动科学发展以改善人们的生活。制药与诊断的综合优势使得罗氏成为个体化医疗的佼佼者。个体化医疗战略旨在以最佳方式为每一位患者提供合适的治疗。

罗氏是领先的生物科技公司之一,提供肿瘤、免疫、传染病、眼科和中央神经系统疾病领域的真正差异化药物。罗氏也是体外诊断和基于组织的肿瘤诊断的世界领导者之一,以及糖尿病管理领域的领跑者。

始创于1896年,罗氏持续寻求预防、诊断和治疗疾病的最佳途径,并对社会做出持续性贡献。罗氏也致力于与所有利益相关者协作,改善患者获得创新医疗的途径。罗氏研发的30多款药物被纳入世界卫生组织基本药物标准清单,其中包括用于挽救生命的抗生素、抗疟药和癌症药物。罗氏已经连续11年被道琼斯可持续发展指数评为制药行业最具可持续性的公司。

罗氏总部位于瑞士巴塞尔,活跃于100多个国家。2019年,全球员工数超98,000人,在研发方面投入了117亿瑞士法郎,销售业绩达615亿瑞士法郎。位于美国的基因泰克公司是罗氏集团的独资子公司。罗氏也是日本中外制药株式会社的控股方。
 
关于百济神州
 
百济神州是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新性药物以为全世界患者提高疗效和药品可及性。百济神州目前在中国大陆、美国、澳大利亚和欧洲拥有3500多名员工,正在加速推动公司多元化的新型癌症疗法药物管线。
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1632593, encodeId=7ae516325939c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Sun Nov 15 16:13:59 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956437, encodeId=adad195643ebb, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Wed Dec 09 10:13:59 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633574, encodeId=4a2116335e4bd, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jun 05 00:13:59 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255060, encodeId=f78e125506021, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336814, encodeId=f97f133681459, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539361, encodeId=48ec1539361cb, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=)]
    2020-11-15 weiz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1632593, encodeId=7ae516325939c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Sun Nov 15 16:13:59 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956437, encodeId=adad195643ebb, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Wed Dec 09 10:13:59 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633574, encodeId=4a2116335e4bd, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jun 05 00:13:59 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255060, encodeId=f78e125506021, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336814, encodeId=f97f133681459, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539361, encodeId=48ec1539361cb, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1632593, encodeId=7ae516325939c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Sun Nov 15 16:13:59 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956437, encodeId=adad195643ebb, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Wed Dec 09 10:13:59 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633574, encodeId=4a2116335e4bd, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jun 05 00:13:59 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255060, encodeId=f78e125506021, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336814, encodeId=f97f133681459, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539361, encodeId=48ec1539361cb, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=)]
    2020-06-05 AspirantSuo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1632593, encodeId=7ae516325939c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Sun Nov 15 16:13:59 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956437, encodeId=adad195643ebb, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Wed Dec 09 10:13:59 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633574, encodeId=4a2116335e4bd, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jun 05 00:13:59 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255060, encodeId=f78e125506021, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336814, encodeId=f97f133681459, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539361, encodeId=48ec1539361cb, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=)]
    2020-05-17 smartjoy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1632593, encodeId=7ae516325939c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Sun Nov 15 16:13:59 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956437, encodeId=adad195643ebb, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Wed Dec 09 10:13:59 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633574, encodeId=4a2116335e4bd, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jun 05 00:13:59 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255060, encodeId=f78e125506021, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336814, encodeId=f97f133681459, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539361, encodeId=48ec1539361cb, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1632593, encodeId=7ae516325939c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Sun Nov 15 16:13:59 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956437, encodeId=adad195643ebb, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Wed Dec 09 10:13:59 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633574, encodeId=4a2116335e4bd, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jun 05 00:13:59 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255060, encodeId=f78e125506021, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336814, encodeId=f97f133681459, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539361, encodeId=48ec1539361cb, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sun May 17 01:13:59 CST 2020, time=2020-05-17, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map